RxDoctor Payments Data

Derek Pantiel, DPM

Primary Podiatric Medicine · Burgaw, NCNPI 1528353638

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.2% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,128 and has fallen 52.4% since, to $537 in 2025.

$3,840in general payments, 2019–2025

Across 117 payments — averaging $32.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Treace Medical Concepts, Inc.$579
  • Convatec Inc.$483
  • Amgen$285
  • Imbed Biosciences Inc.$253
  • Organogenesis Inc.$238
  • Nevro Corp.$188
  • plus $2K from 27 others

What the payments were for

  • Travel & lodging$3389%
  • Food & beverage$3,50291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,840 in reported general payments places this provider in the 80th percentile of 64 primary podiatric medicine providers in North Carolina.

See all primary podiatric medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$170,949
Medicare patients
770
Services billed
2,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole11$14,867
Ciclopirox116$5,053
Calcipotriene14$4,648
Piroxicam15$4,527
Lidocaine-PrilocaineLidocaine/Prilocaine25$3,975
Ammonium Lactate111$2,987
Ketoconazole105$2,559
Mupirocin138$972
Gabapentin64$560
Diclofenac Sodium12$472
Triamcinolone Acetonide14$329
Doxycycline Monohydrate20$304
Cephalexin51$273
Clindamycin Hcl28$157
Methylprednisolone30$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$21$14,86711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 primary podiatric medicine providers in North Carolina.

Other primary podiatric medicine in Burgaw

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →